Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.02 by 12.75 percent. This is a 2400 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $45.891 million which missed the analyst consensus estimate of $50.793 million by 9.65 percent. This is a 144.70 percent increase over sales of $18.754 million the same period last year.